{"nctId":"NCT01448057","briefTitle":"Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu","startDateStruct":{"date":"2013-07"},"conditions":["Upper Respiratory Tract Infection","Nasal Congestion","Rhinorrhea","Sneezing"],"count":341,"armGroups":[{"label":"Combination Product","type":"EXPERIMENTAL","interventionNames":["Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets"]},{"label":"Paracetamol tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Paracetamol (500 mg) tablets"]}],"interventions":[{"name":"Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets","otherNames":[]},{"name":"Paracetamol (500 mg) tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Inclusion criteria:\n\n  â€¢ acute URTI, diagnosed by a health care professional at the study site, with the following symptoms having started within 72 hours before the screening/baseline Visit: nasal congestion, sneezing, and rhinorrhea.\n* Exclusion criteria:\n\n  * Use of other investigational drugs within 30 days or 10 half-lives before enrollment, whichever is longer.\n  * History of or known hypersensitivity to any of the study drugs, excipients or to drugs of similar chemical classes.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Physician Global Evaluation of Effectiveness on Nasal Symptoms","description":"The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2.\n\nRange from 1 to 5 where 1 is excellent and 5 is bad :\n\n1 = excellent : 75% to 100% remission of signs and symptoms 5 = bad : exacerbation of nasal symptoms","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.84"},{"groupId":"OG001","value":"2.1","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms","description":"Subject will assess Nasal and non Nasal symptoms using a 100 mm Visual Analog Scale for each symptom, 0=no symptoms 100= the worst possible symptoms","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169.2","spread":"231.14"},{"groupId":"OG001","value":"225.3","spread":"262.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":170},"commonTop":["somnolence","Abdominal pain"]}}}